ProShare Advisors LLC Purchases 11,729 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

ProShare Advisors LLC raised its position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 40.2% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 40,875 shares of the company's stock after acquiring an additional 11,729 shares during the period. ProShare Advisors LLC's holdings in Vaxcyte were worth $3,346,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the company. CIBC Asset Management Inc raised its stake in shares of Vaxcyte by 5.5% in the fourth quarter. CIBC Asset Management Inc now owns 3,307 shares of the company's stock valued at $271,000 after purchasing an additional 171 shares in the last quarter. Bridgefront Capital LLC raised its stake in shares of Vaxcyte by 4.2% in the 4th quarter. Bridgefront Capital LLC now owns 4,244 shares of the company's stock valued at $347,000 after buying an additional 172 shares in the last quarter. Smartleaf Asset Management LLC lifted its holdings in shares of Vaxcyte by 188.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock worth $33,000 after acquiring an additional 260 shares during the period. Catalyst Funds Management Pty Ltd lifted its holdings in shares of Vaxcyte by 1.7% during the 4th quarter. Catalyst Funds Management Pty Ltd now owns 18,400 shares of the company's stock worth $1,506,000 after acquiring an additional 300 shares during the period. Finally, Whipplewood Advisors LLC acquired a new stake in shares of Vaxcyte during the 4th quarter valued at about $28,000. Institutional investors own 96.78% of the company's stock.

Insiders Place Their Bets

In other news, COO Jim Wassil sold 8,000 shares of Vaxcyte stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $73.27, for a total transaction of $586,160.00. Following the completion of the sale, the chief operating officer now owns 154,931 shares in the company, valued at $11,351,794.37. The trade was a 4.91% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 3.10% of the company's stock.

Analysts Set New Price Targets

PCVX has been the subject of several recent research reports. The Goldman Sachs Group dropped their price target on shares of Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Guggenheim restated a "buy" rating and set a $160.00 target price on shares of Vaxcyte in a research report on Wednesday, March 12th. Needham & Company LLC reaffirmed a "buy" rating and issued a $90.00 price target on shares of Vaxcyte in a research note on Tuesday, April 8th. Bank of America lowered their price target on Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Finally, Evercore ISI raised Vaxcyte to a "strong-buy" rating in a report on Monday, March 31st. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Vaxcyte currently has a consensus rating of "Buy" and a consensus price target of $136.50.

Vaxcyte Stock Up 0.6%

Vaxcyte stock opened at $32.03 on Tuesday. The stock has a 50-day simple moving average of $41.73 and a 200 day simple moving average of $70.94. The stock has a market capitalization of $4.13 billion, a price-to-earnings ratio of -6.96 and a beta of 1.27. Vaxcyte, Inc. has a 12-month low of $27.66 and a 12-month high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($1.04) earnings per share for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). During the same period in the prior year, the company earned ($0.85) EPS. As a group, sell-side analysts anticipate that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

Want to see what other hedge funds are holding PCVX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vaxcyte, Inc. (NASDAQ:PCVX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.